Matinas BioPharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MTNB and other ETFs, options, and stocks.

About MTNB

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. 

CEO
Jerome D. Jabbour
CEOJerome D. Jabbour
Employees
7
Employees7
Headquarters
Bedminster, New Jersey
HeadquartersBedminster, New Jersey
Founded
2013
Founded2013
Employees
7
Employees7

MTNB Key Statistics

Market cap
4.19M
Market cap4.19M
Price-Earnings ratio
-0.20
Price-Earnings ratio-0.20
Dividend yield
Dividend yield
Average volume
30.65K
Average volume30.65K
High today
$0.7005
High today$0.7005
Low today
$0.6401
Low today$0.6401
Open price
$0.671
Open price$0.671
Volume
21.02K
Volume21.02K
52 Week high
$3.09
52 Week high$3.09
52 Week low
$0.4748
52 Week low$0.4748

Stock Snapshot

With a market cap of 4.19M, Matinas BioPharma(MTNB) trades at $0.64. The stock has a price-to-earnings ratio of -0.20.

During the trading session on 2026-01-20, Matinas BioPharma(MTNB) shares reached a daily high of $0.70 and a low of $0.64. At a current price of $0.64, the stock is 0.0% higher than the low and still -8.6% under the high.

Trading volume for Matinas BioPharma(MTNB) stock has reached 21.02K, versus its average volume of 30.65K.

Over the past 52 weeks, Matinas BioPharma(MTNB) stock has traded between a high of $3.09 and a low of $0.47.

Over the past 52 weeks, Matinas BioPharma(MTNB) stock has traded between a high of $3.09 and a low of $0.47.

People also own

Based on the portfolios of people who own MTNB. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .